Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual MeetingGlobeNewsWire • 12/10/22
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual MeetingGlobeNewsWire • 12/05/22
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)GlobeNewsWire • 12/01/22
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/21/22
New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from ResultsGlobeNewsWire • 11/21/22
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/04/22
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood CancersGlobeNewsWire • 10/11/22
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022GlobeNewsWire • 10/05/22
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 MillionGlobeNewsWire • 09/12/22
Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare ConferenceGlobeNewsWire • 09/02/22
Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season?Zacks Investment Research • 08/02/22
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell LymphomaGlobeNewsWire • 07/28/22
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/27/22
Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022GlobeNewsWire • 07/08/22
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme DiseaseGlobeNewsWire • 06/15/22
Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment TechnologyGlobeNewsWire • 06/02/22